Get the Stockscreener App
0.7884
0.82%
-0.0065
After Hours:
.80
0.0116
+1.47%
Milestone Pharmaceuticals Inc stock is traded at $0.7884, with a volume of 1.26M.
It is down -0.82% in the last 24 hours and down -32.03% over the past month.
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
See More
Previous Close:
$0.7949
Open:
$0.8
24h Volume:
1.26M
Relative Volume:
0.85
Market Cap:
$98.15M
Revenue:
$1.78M
Net Income/Loss:
$-68.36M
P/E Ratio:
-1.1547
EPS:
-0.6828
Net Cash Flow:
$-51.59M
1W Performance:
-13.91%
1M Performance:
-32.03%
6M Performance:
-36.93%
1Y Performance:
-59.98%
1-Day Range:
$0.7521
$0.815
1-Week Range:
$0.7521
$0.929
52-Week Range:
$0.7521
$3.06
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
Name
Milestone Pharmaceuticals Inc
Sector
Industry
Phone
(514) 336-0444
Address
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Compare MIST vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
0.7884 | 98.15M | 1.78M | -68.36M | -51.59M | -0.6828 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Raymond James | Strong Buy |
| Dec-15-25 | Upgrade | TD Cowen | Hold → Buy |
| Sep-11-25 | Initiated | Wells Fargo | Overweight |
| Jun-05-25 | Resumed | H.C. Wainwright | Buy |
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Jun-20-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-22-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-05-21 | Initiated | H.C. Wainwright | Buy |
| Jul-29-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-24-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-25-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-24-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-24-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-04-19 | Initiated | Oppenheimer | Outperform |
| Jun-03-19 | Initiated | Cowen | Outperform |
| Jun-03-19 | Initiated | Jefferies | Buy |
| Jun-03-19 | Initiated | Piper Jaffray | Overweight |
View All
Milestone Pharmaceuticals Inc Stock (MIST) Latest News
Milestone Pharmaceuticals (MIST) Expands ReVeRA-301 Trial with M - GuruFocus
Montreal Heart Institute enrolls first Canadian patient in AFib trial - Investing.com
Milestone Pharmaceuticals Inc. (MIST) Stock Price, News, Quote & History - Yahoo! Finance Canada
A Canadian patient joins a trial of a self-administered nasal spray for sudden fast heartbeats. - Stock Titan
Milestone Pharmaceuticals stock falls 6.41 percent after Q2 miss - AD HOC NEWS
H.C. Wainwright Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Milestone Pharmaceuticals stock stays near $0.92 after China approval - AD HOC NEWS
Milestone Pharmaceuticals at H.C. Wainwright: launch gains and afib push By Investing.com - Investing.com Canada
MIST: Rapid drug launch, strong provider uptake, and AFib trial progress drive growth outlook - TradingView
Milestone Pharmaceuticals Inc. (MIST) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Milestone Pharmaceuticals at Wells Fargo: launch gains, bigger test ahead By Investing.com - Investing.com South Africa
Milestone Pharma's nasal spray gets first ex-US approval - The Pharma Letter
Milestone Pharmaceuticals Inc. (MIST) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
MIST Reiterated by HC Wainwright & Co. -- Price Target Maintained at $8.00 - GuruFocus
Milestone Pharmaceuticals (MIST) Gains China Approval for Etripa - GuruFocus
Milestone Pharmaceuticals Says NMPA Approval Triggers $2 Mln Milestone Payment To The Co - TradingView
Milestone Pharmaceuticals Announces China NMPA Approval of Etripamil for PSVT, Triggering $2 Million Milestone Payment - Quiver Quantitative
Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States - finance.yahoo.com
Milestone Pharmaceuticals Announces China NMPA Approval of Etripamil for PSVT, Triggering $2 Million Milestone Payment | MIST Stock News - Quiver Quantitative
Nxera Pharma to Receive $8.6 Million Milestone Payment from Centessa Pharmaceuticals Following Late-stage Development Progress - Yahoo Finance
Milestone Pharmaceuticals Inc. (MIST) Key Financial Ratios – Valuation, Profitability & More - Value Research
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences - manilatimes.net
Three investor events are set for Boston and New York, with Milestone joining - Stock Titan
Milestone Pharmaceuticals stock holds at $1.16 as fundamentals and outlook stay in focus - AD HOC NEWS
Milestone presents study on PSVT impact between episodes By Investing.com - Investing.com Canada
Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes - manilatimes.net
Milestone presents study on PSVT impact between episodes - Investing.com
First Patient Enrolled in the Phase 3 ReVeRA-301 Pivotal Trial for Afib - dicardiology.com
Milestone (MIST) Quarter in Focus: The Bottom-Line Figure Trails Its Comparison under the Current Snapshot; Closing Reaction: Shares Finish 1.42% Lower on the DayEnergy Earnings Report - vinanet.vn
Milestone (MIST) Earnings Snapshot: Reported EPS Misses Expectations for the Current Session; Stock Move: Shares Finish 1.90% Lower in the Current UpdateEarnings Recovery Stocks - vinanet.vn
Milestone (MIST) Results Breakdown: EPS Comes in Below Forecast in Latest Trading; Latest Reaction: The Stock Records a 2.43% Increase for the Current SessionFree Cash Flow Trends - vinanet.vn
Milestone Pharmaceuticals (NASDAQ:MIST) Advances Trial Path - Kalkine Media
Milestone (MIST) Snapshot: Ends Higher by 0.97% at $1.04 in Latest Trading; Next Session: Traders Can Monitor the $0.99-$1.09 Range on the DayValue ETF - vinanet.vn
Milestone Pharmaceuticals begins phase 3 trial for AFib treatment By Investing.com - Investing.com Nigeria
Milestone Pharmaceuticals shares rise as first patient enters Phase 3 AFib trial - Yahoo Finance
Milestone Pharmaceuticals stock gains on Phase 3 AFib trial By Investing.com - Investing.com Nigeria
Milestone Pharmaceuticals (MIST) Launches Phase 3 Trial Amidst High Price-to-Sales Valuation - GuruFocus
Milestone Pharmaceuticals stock gains on Phase 3 AFib trial - Investing.com
Milestone Pharmaceuticals begins phase 3 trial for AFib treatment - Investing.com
Milestone Pharmaceuticals Enrolls First Patient in Phase 3 ReVeRA-301 Trial of Etripamil for AFib-RVR - Quiver Quantitative
Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR) - The Manila Times
This Sphere Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Sahm
Cantor Fitzgerald initiates Milestone Pharmaceuticals stock coverage with overweight rating - Investing.com Canada
MIST Initiated Coverage by Cantor Fitzgerald -- Rating Overweight - GuruFocus
Cantor Fitzgerald Initiates Milestone Pharmaceuticals at Overweight With $3 Price Target - Yahoo Finance
Milestone Pharmaceuticals: Reiterating Sell As The Losses Compound (NASDAQ:MIST) - Seeking Alpha
Milestone Pharmaceuticals (MIST) Climbs 2.8% as Shares Hold Above $1.04 SupportShort Setup Alerts - vinanet.vn
Milestone’s FDA Win Now Faces A Tougher Test: Sales - Finimize
What is HC Wainwright's Forecast for MIST Q3 Earnings? - MarketBeat
TD Cowen Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Earnings To Watch: Milestone Scientific Inc (MLSS) Q2 2026 -- GF Value Sees 13% Upside - finance.yahoo.com
Milestone Pharmaceuticals Inc Stock (MIST) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):